Medtech Worried After UK HTA Body Moots Pharma Guidance Fees
Executive Summary
The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.
You may also be interested in...
Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs
UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.
As Appraisal Fees Loom, NICE Says No To Industry Calls For Reform
A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.
UK Life Sciences Vows To Maximize Post-Brexit Opportunities
The UK is “open for business” as far as the life-sciences sector is concerned, and those with ministerial and departmental oversight are promising to work with the realities – still largely unknown – that the country's exit from the EU will bring forth. Such was the tone of UK Office for Life Sciences’ director Nicole Mather, speaking to health-care industry delegates Sept. 15 in London.